Alvotech buys Xbrane R&D and expands presence in Sweden

• Xbrane deal completion 4 June https://insights.citeline.com/generics-bulletin/business/deals/alvotech-snaps-up-xbranes-rd-and-cimzia-rival-for-27m-ANHE6U2UPFGWVF2D3L7VRVCQW4/

On 4 June, Alvotech completed the acquisition announced in March of Xbrane Biopharma AB’s (“Xbrane”) R&D operations and biosimilar candidate XB003, referencing Cimzia® (certolizumab pegol). 
The integration of Xbrane's R&D team and facilities ffurther expanding Alvotech’s development capabilities, and establishes a firm footprint in the Swedish life science sector. Xbrane’s R&D operations are based in Campus Solna, at the Karolinska Institute outside Stockholm.